S&P Futures
5,968.75 +10.50 (+0.18%) Dow Futures
43,968.00 +67.00 (+0.15%) Nasdaq Futures
20,944.50 +50.50 (+0.24%) Russell 2000 Futures
2,413.20 +7.40 (+0.31%) Crude Oil
71.20 -0.49 (-0.68%) Gold
2,670.50 -5.80 (-0.22%)
Avenue Therapeutics, Inc. (ATXI)
After hours:
| Previous Close | 2.2200 |
| Open | 2.2500 |
| Bid | 2.1700 x 100 |
| Ask | 2.3800 x 100 |
| Day's Range | 2.2400 - 2.3300 |
| 52 Week Range | 1.7000 - 26.4750 |
| Volume | |
| Avg. Volume | 44,450 |
| Market Cap | 3.206M |
| Beta (5Y Monthly) | -0.18 |
| PE Ratio (TTM) | 0.06 |
| EPS (TTM) | 37.4800 |
| Earnings Date | Nov 11, 2024 - Nov 15, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.00 |
GlobeNewswireAvenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET. The fireside chat will be av
- GlobeNewswire
Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment ConferenceDate: Monday, September 9, 2024Loc
